Godavari Drugs Ltd

BSE: 530317

19

total announcements

GODAVARI.BO · 15 min delayed

Key Stats · Yahoo Finance · as of 15 Oct 2026

Market Cap

₹144 Cr

P/E (TTM)

25.9

EPS (TTM)

₹5.08

52W Low

₹69.70

52W High

₹144.35

Dividend Yield

0.00%

Beta

0.45

Price / Book

1.3

Debt / Equity

100.7

Revenue (TTM)

₹111 Cr

Gross Margin

27.71%

Operating Margin

7.38%

AnnouncementsDiscussion
BSEGeneralFundraise1d ago

Godavari Drugs Ltd

The Board of Directors of Godavari Drugs Limited, at its meeting held on 14th October, 2026, approved availing of Working Capital Limits up to Rs. 340 Million from ICICI Bank Limited and authorised the Managing Director to complete the necessary formalities. The outcome is enclosed.

Godavari Drugs Ltd has approved availing of Working Capital Limits up to Rs. 340 Million from ICICI Bank Limited, with the Managing Director authorized to complete necessary formalities.

Read more →📎 1 attachment
BSEAGM/EGM25 Sept 2026

Godavari Drugs Ltd

Proceedings of the 38th AGM held on 25.09.2026

Godavari Drugs Ltd held its 38th Annual General Meeting (AGM) on September 25, 2026, through video conferencing. 86 members were present, and all directors attended through video conferencing. The meeting was conducted in compliance with the Companies Act, 2013, and circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI).

Read more →📎 1 attachment
BSECompany Update3 Sept 2026

Godavari Drugs Ltd

We hereby inform that the company has dispatched a physical letter to the shareholders whose email addresses are not registered with the company/RTA/Depositories/DP. The Letter contains ....

Godavari Drugs Ltd has dispatched physical letters to shareholders whose email addresses are not registered with the company, providing a weblink and QR code to access the notice for the 38th Annual General Meeting to be held on September 25, 2026.

Read more →📎 1 attachment
BSEOthersResults1 Sept 2026

Godavari Drugs Ltd

The Company informed that the 38th AGM of the Company is scheduled to be held on Friday, the 25th Sep 2026 at 03.00 pm through Video Conferencing/ other Audio Visual means in accordance ....

Godavari Drugs Ltd has announced its 38th AGM and Annual Report for FY 2025-26, highlighting the company's progress, investments in manufacturing infrastructure, product development, and technology, and its strategy to diversify beyond its established product portfolio.

Read more →📎 1 attachment
BSECompany UpdateM&A1 Sept 2026

Godavari Drugs Ltd

Amendment to MOA of the company was approved by Board of Directors. The Proposed change in MOA of the company is subject to necessary approvals from Ministry of Corporate Affairs, Shareholders ....

Godavari Drugs Ltd has approved an alteration to its Memorandum of Association to include a new Main Object for the business of nutraceuticals, dietary supplements, and allied products. The alteration requires approval from the shareholders by way of a Special Resolution at the 38th Annual General Meeting scheduled for September 25, 2026.

Read more →📎 1 attachment
BSEOthersExpansion31 Aug 2026

Godavari Drugs Ltd

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we inform that the Board of Directors at its meeting held on 31st August, 2026 approved the following: 1. Alteration of the ....

Godavari Drugs Ltd has announced that its Board of Directors has approved the alteration of the Main Objects Clause III(A) of the Memorandum of Association to include the business of nutraceuticals, dietary supplements, natural extracts, food ingredients, and allied products. The company also revised the notice convening the 38th Annual General Meeting to be held on September 25, 2026.

Read more →📎 1 attachment
BSECompany UpdateFundraise14 Aug 2026

Godavari Drugs Ltd

Board of Directors of the Company in its meeting held on Friday, 14th August, 2026 at 11.45 A.M. approved and passed the resolution for allotment of Equity Shares on conversion of 7,86,690 ....

Godavari Drugs Ltd has announced the allotment of 7,86,690 equity shares on conversion of warrants to promoters at an issue price of Rs. 89/- each, increasing the paid-up equity capital from Rs. 10,12,74,350/- to Rs. 10,91,41,250/-.

Read more →📎 1 attachment
BSEBoard MeetingResults11 Aug 2026

Godavari Drugs Ltd

Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Update on board meeting - Intimation ....

Godavari Drugs Ltd has issued a corrigendum to correct a typographical error in its earlier intimation letter regarding the Board Meeting scheduled on 14/08/2026 to consider and approve the Un-Audited Financial Results for the first quarter ended 30/06/2026.

Read more →📎 1 attachment
BSEInsider Trading / SAST23 Jun 2026

Godavari Drugs Ltd

Intimation of Closure of Trading window for the quarter ended June 30, 2026

Godavari Drugs Ltd has announced the closure of its trading window for Designated Persons and their immediate relatives from July 1, 2026, until 48 hours after the declaration of un-audited financial results for the quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent insider trading ahead of financial disclosures.

Read more →📎 1 attachment